- Tytuł:
-
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3
mutation . - Autorzy:
- Źródło:
- Leukemia & lymphoma [Leuk Lymphoma] 2019 Jul; Vol. 60 (7), pp. 1626-1631. Date of Electronic Publication: 2019 Apr 18.
- Typ publikacji:
- Case Reports; Journal Article; Research Support, Non-U.S. Gov't
- MeSH Terms:
-
Mutation *
Drug Resistance, Neoplasm/*drug effects
Janus Kinase 3/*genetics
Leukemia, Prolymphocytic, T-Cell/*drug therapy
Piperidines/*therapeutic use
Protein Kinase Inhibitors/*therapeutic use
Pyrazoles/*therapeutic use
Pyrimidines/*therapeutic use
Pyrroles/*therapeutic use
Drug Therapy, Combination ; Humans ; Janus Kinase 1/antagonists & inhibitors ; Janus Kinase 2/antagonists & inhibitors ; Male ; Middle Aged ; Nitriles ; Prognosis
Czasopismo naukowe